Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive malignancy that usually presents with diffuse cutaneous lesions. While a favorable response to therapy occurs in a majority of cases, a sustained long-term response is uncommon. Most patients subsequently relapse within a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2011/651906 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690053489459200 |
|---|---|
| author | Amir Steinberg Rina Kansal Matthew Wong Angela Lopez Stephen Lim Jean Lopategui Michael Lill |
| author_facet | Amir Steinberg Rina Kansal Matthew Wong Angela Lopez Stephen Lim Jean Lopategui Michael Lill |
| author_sort | Amir Steinberg |
| collection | DOAJ |
| description | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive malignancy that usually presents with diffuse cutaneous lesions. While a favorable response to therapy occurs in a majority of cases, a sustained long-term response is uncommon. Most patients subsequently relapse within a year. In the following report, we present the case of a 41-year-old woman who has not displayed many of the clinical features traditionally associated with BPDCN. The patient received sporadic chemotherapy treatment over the course of 2 years, before undergoing an allogeneic stem cell transplant. Although she ultimately relapsed following her transplant, her disease has repeatedly returned into remission after donor lymphocyte infusion (DLI). Currently, the patient is in remission following her fourth DLI. We believe that allogeneic transplantation should be considered as front-line therapy for the treatment of this rare malignancy. |
| format | Article |
| id | doaj-art-ecb27855a06c4e4b88de7194dbaa0955 |
| institution | DOAJ |
| issn | 2090-6943 2090-6951 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Transplantation |
| spelling | doaj-art-ecb27855a06c4e4b88de7194dbaa09552025-08-20T03:21:26ZengWileyCase Reports in Transplantation2090-69432090-69512011-01-01201110.1155/2011/651906651906Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following TransplantAmir Steinberg0Rina Kansal1Matthew Wong2Angela Lopez3Stephen Lim4Jean Lopategui5Michael Lill6Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USACedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USACedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USACedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USACedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USACedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USACedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USABlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive malignancy that usually presents with diffuse cutaneous lesions. While a favorable response to therapy occurs in a majority of cases, a sustained long-term response is uncommon. Most patients subsequently relapse within a year. In the following report, we present the case of a 41-year-old woman who has not displayed many of the clinical features traditionally associated with BPDCN. The patient received sporadic chemotherapy treatment over the course of 2 years, before undergoing an allogeneic stem cell transplant. Although she ultimately relapsed following her transplant, her disease has repeatedly returned into remission after donor lymphocyte infusion (DLI). Currently, the patient is in remission following her fourth DLI. We believe that allogeneic transplantation should be considered as front-line therapy for the treatment of this rare malignancy.http://dx.doi.org/10.1155/2011/651906 |
| spellingShingle | Amir Steinberg Rina Kansal Matthew Wong Angela Lopez Stephen Lim Jean Lopategui Michael Lill Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant Case Reports in Transplantation |
| title | Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant |
| title_full | Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant |
| title_fullStr | Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant |
| title_full_unstemmed | Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant |
| title_short | Good Clinical Response in a Rare Aggressive Hematopoietic Neoplasm: Plasmacytoid Dendritic Cell Leukemia with No Cutaneous Lesions Responding to 4 Donor Lymphocyte Infusions Following Transplant |
| title_sort | good clinical response in a rare aggressive hematopoietic neoplasm plasmacytoid dendritic cell leukemia with no cutaneous lesions responding to 4 donor lymphocyte infusions following transplant |
| url | http://dx.doi.org/10.1155/2011/651906 |
| work_keys_str_mv | AT amirsteinberg goodclinicalresponseinarareaggressivehematopoieticneoplasmplasmacytoiddendriticcellleukemiawithnocutaneouslesionsrespondingto4donorlymphocyteinfusionsfollowingtransplant AT rinakansal goodclinicalresponseinarareaggressivehematopoieticneoplasmplasmacytoiddendriticcellleukemiawithnocutaneouslesionsrespondingto4donorlymphocyteinfusionsfollowingtransplant AT matthewwong goodclinicalresponseinarareaggressivehematopoieticneoplasmplasmacytoiddendriticcellleukemiawithnocutaneouslesionsrespondingto4donorlymphocyteinfusionsfollowingtransplant AT angelalopez goodclinicalresponseinarareaggressivehematopoieticneoplasmplasmacytoiddendriticcellleukemiawithnocutaneouslesionsrespondingto4donorlymphocyteinfusionsfollowingtransplant AT stephenlim goodclinicalresponseinarareaggressivehematopoieticneoplasmplasmacytoiddendriticcellleukemiawithnocutaneouslesionsrespondingto4donorlymphocyteinfusionsfollowingtransplant AT jeanlopategui goodclinicalresponseinarareaggressivehematopoieticneoplasmplasmacytoiddendriticcellleukemiawithnocutaneouslesionsrespondingto4donorlymphocyteinfusionsfollowingtransplant AT michaellill goodclinicalresponseinarareaggressivehematopoieticneoplasmplasmacytoiddendriticcellleukemiawithnocutaneouslesionsrespondingto4donorlymphocyteinfusionsfollowingtransplant |